Nektar Therapeutics (NASDAQ:NKTR) Earns Buy Rating from Analysts at HC Wainwright

Stock analysts at HC Wainwright started coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research note issued on Tuesday, Marketbeat Ratings reports. The firm set a “buy” rating and a $6.50 price target on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Nektar Therapeutics’ Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.65) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($0.79) EPS.

Several other equities research analysts also recently weighed in on NKTR. BTIG Research reiterated a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a research note on Monday, September 30th. Piper Sandler started coverage on Nektar Therapeutics in a research note on Monday, November 4th. They set an “overweight” rating and a $7.00 price objective for the company. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $4.10.

Nektar Therapeutics Price Performance

Shares of NASDAQ:NKTR opened at $1.02 on Tuesday. Nektar Therapeutics has a 1-year low of $0.46 and a 1-year high of $1.93. The stock has a market cap of $188.15 million, a P/E ratio of -1.21 and a beta of 0.57. The firm has a fifty day moving average price of $1.23 and a 200 day moving average price of $1.25.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC lifted its position in Nektar Therapeutics by 30.4% in the third quarter. SG Americas Securities LLC now owns 95,637 shares of the biopharmaceutical company’s stock valued at $124,000 after purchasing an additional 22,285 shares during the period. Victory Capital Management Inc. purchased a new position in shares of Nektar Therapeutics during the 2nd quarter worth approximately $29,000. Valence8 US LP purchased a new position in shares of Nektar Therapeutics during the 3rd quarter worth approximately $34,000. Jane Street Group LLC lifted its holdings in shares of Nektar Therapeutics by 50.0% in the 3rd quarter. Jane Street Group LLC now owns 91,470 shares of the biopharmaceutical company’s stock valued at $119,000 after buying an additional 30,481 shares during the period. Finally, Intech Investment Management LLC purchased a new stake in shares of Nektar Therapeutics in the third quarter valued at approximately $41,000. 75.88% of the stock is currently owned by institutional investors and hedge funds.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.